Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.

Subjects

Subjects :

Adult
Aged
Angiogenesis Inhibitors administration & dosage
Angiogenesis Inhibitors adverse effects
Angiogenesis Inhibitors pharmacology
Angiogenesis Inhibitors therapeutic use
Antineoplastic Agents adverse effects
Antineoplastic Agents pharmacology
Antineoplastic Agents therapeutic use
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols pharmacology
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Arsenic Trioxide
Arsenicals adverse effects
Arsenicals pharmacology
Arsenicals therapeutic use
Ascorbic Acid adverse effects
Ascorbic Acid pharmacology
Ascorbic Acid therapeutic use
Azacitidine administration & dosage
Azacitidine adverse effects
Azacitidine pharmacology
Azacitidine therapeutic use
Bone Marrow blood supply
Bone Marrow drug effects
Bone Marrow Cells drug effects
Bone Marrow Cells metabolism
Cohort Studies
Decitabine
Dose-Response Relationship, Drug
Female
Gene Expression Profiling
Humans
Leukemia, Myeloid, Acute metabolism
Male
Middle Aged
Myelodysplastic Syndromes metabolism
Neovascularization, Pathologic drug therapy
Oxides adverse effects
Oxides pharmacology
Oxides therapeutic use
Young Adult
Antineoplastic Agents administration & dosage
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Arsenicals administration & dosage
Ascorbic Acid administration & dosage
Azacitidine analogs & derivatives
Leukemia, Myeloid, Acute drug therapy
Myelodysplastic Syndromes drug therapy
Oxides administration & dosage

Details

Language :

English

ISSN :

1096-8652

Volume :

86

Issue :

9

Database :

MEDLINE

Journal :

American journal of hematology

Publication Type :

Academic Journal

Accession number :

21815182

Full Text :

https://doi.org/10.1002/ajh.22092